# Study of GSK2862277 in Subjects Undergoing Oesophagectomy Surgery

> **NCT02221037** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 35 (actual)

## Conditions studied

- Lung Injury, Acute and Respiratory Distress Syndrome, Adult

## Interventions

- **DRUG:** GSK2862277
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02221037
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-28
- **Primary completion:** 2017-06-28
- **Final completion:** 2017-06-28
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** The study was terminated on the basis that protocol defined stopping criteria had been met.
- **Last updated:** 2020-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02221037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02221037, "Study of GSK2862277 in Subjects Undergoing Oesophagectomy Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02221037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*